Does Blue Cross Blue Shield of North Carolina Cover Viagra for Women?

What You Actually Need to Know Before Calling BCBS NC

The short answer is no, Blue Cross Blue Shield of North Carolina does not cover Viagra (sildenafil) when prescribed for female sexual dysfunction. The reason is straightforward: the FDA has never approved sildenafil for this purpose in women. Insurance companies, including BCBS NC, generally tie coverage decisions to FDA-approved indications, and off-label prescribing for sexual dysfunction in women falls outside that boundary.

The full picture is more nuanced, and your specific situation matters. Sildenafil carries an FDA approval under the brand name Revatio at a 20 mg dose for pulmonary arterial hypertension (PAH), a condition that disproportionately affects women at a ratio of roughly 4:1 compared with men. If you have PAH, BCBS NC plans typically do cover Revatio, though prior authorization is almost always required. Sexual dysfunction and PAH are different clinical problems with different coverage pathways.

For women who are dealing with low libido, arousal difficulties, or pain during sex, the conversation with your insurer should probably start with a different drug category entirely.

How BCBS NC Handles Prescription Drug Coverage Generally

Formulary Tiers and What They Mean for You

BCBS NC offers several plan types, including State Health Plan options for state employees, ACA marketplace plans, and employer-sponsored group plans. Each plan has its own formulary, which is a tiered list of covered drugs. Sildenafil (generic Viagra) typically appears on formularies for male erectile dysfunction at Tier 2 or Tier 3, meaning moderate cost-sharing applies to men with a prescription.

For women, the formulary picture looks different. Because there is no FDA-approved indication for sildenafil in female sexual dysfunction, the drug does not appear on the BCBS NC formulary for that purpose. A pharmacist filling a prescription written for "female sexual dysfunction" would find the claim denied.

Prior Authorization and Step Therapy

Even for covered drugs, BCBS NC may require prior authorization (PA), meaning your provider must submit documentation showing medical necessity before the plan will pay. Step therapy is a related requirement: you must try and fail a preferred drug before the plan covers a more expensive one.

For the two FDA-approved drugs targeting female sexual interest/arousal disorder (FSIAD), flibanserin and bremelanotide, prior authorization is commonly required. Your OB-GYN, gynecologist, or women's health NP will need to document your diagnosis using recognized terminology and show that other interventions were considered.

How to Check Your Specific Plan

Rather than relying on general rules, take these concrete steps:

1. Call the member services number on the back of your BCBS NC insurance card and ask: "Is flibanserin (Addyi) or bremelanotide (Vyleesi) covered on my formulary?"
2. Ask specifically about the tier, any PA requirements, and whether step therapy applies.
3. Request the formulary exception process information in writing.
4. Have your provider submit a Letter of Medical Necessity that uses DSM-5 language for FSIAD or ICD-10 code F52.0 (hypoactive sexual desire disorder).

The Two FDA-Approved Drugs for Female Sexual Dysfunction

Flibanserin (Addyi): The Daily Pill

Flibanserin was approved by the FDA in August 2015 for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is a non-hormonal drug that acts on serotonin and dopamine receptors in the brain, which is mechanically different from how sildenafil works (sildenafil targets blood vessel dilation through PDE5 inhibition).

The standard dose is 100 mg taken once daily at bedtime. The FDA's approval came with a Risk Evaluation and Mitigation Strategy (REMS) because of the interaction with alcohol: combining flibanserin and alcohol can cause severe hypotension and syncope. Your prescriber must be certified through the REMS program to prescribe it.

In the key trials (BEGONIA, SNOWDROP, and VIOLET), flibanserin produced a statistically significant increase in satisfying sexual events compared with placebo, though the absolute difference was modest: roughly 0.5 to 1.0 additional satisfying sexual events per month.

The FDA approval covers premenopausal women. Use in postmenopausal women is off-label, which is a real evidence gap that your provider should discuss with you directly.

Bremelanotide (Vyleesi): The As-Needed Injection

Bremelanotide received FDA approval in June 2019 for HSDD in premenopausal women. Unlike flibanserin, bremelanotide is used on demand: you inject it subcutaneously at least 45 minutes before anticipated sexual activity, and no more than once per 24 hours or eight times per month.

The dose is 1.75 mg per injection, delivered via an autoinjector pen to the abdomen or thigh. The most common side effects are nausea (affecting roughly 40% of women in trials), flushing, and transient blood pressure changes. Clinical trial data from the RECONNECT studies showed a statistically significant improvement in desire and reduction in distress compared with placebo.

One practical note: bremelanotide is generally more expensive than flibanserin at list price, which makes the insurance coverage question particularly important for this drug.

Why Sildenafil Is Sometimes Prescribed Off-Label for Women Anyway

Despite the lack of FDA approval for female sexual dysfunction, some clinicians do prescribe sildenafil off-label for women, particularly for arousal difficulties related to insufficient genital blood flow. The science is not absent; it is just not definitive.

A 2008 study published in JAMA examined sildenafil in women with sexual arousal disorder secondary to antidepressant use, specifically SSRIs. Women on SSRIs who took sildenafil 50 mg showed significantly greater improvement in orgasm and overall satisfaction scores compared with placebo. This is one of the cleaner datasets supporting off-label use in a specific female population.

A separate body of work has looked at sildenafil in women with spinal cord injuries, where genital engorgement is impaired neurologically. Results were promising but trial sizes were small.

Here is a framework for thinking about whether off-label sildenafil makes clinical sense for you specifically, based on the available evidence:

Off-label sildenafil may have the most supporting data in women who have:

• SSRI-induced sexual dysfunction (arousal/orgasm subtype specifically)
• Neurogenic sexual dysfunction from spinal cord injury or multiple sclerosis
• Clitoral engorgement difficulties rather than desire difficulties

Off-label sildenafil has the least supporting data in women who have:

• Primary hypoactive sexual desire disorder without an identifiable physiological cause
• Menopause-related sexual dysfunction where vaginal atrophy is the primary driver
• Hormonal contraception-related sexual side effects

Even where off-label use makes sense clinically, BCBS NC will almost certainly not cover it for female sexual dysfunction. The cost of generic sildenafil without insurance runs approximately $30 to $80 per month through discount programs like GoodRx, which makes it one of the more affordable options if you and your provider decide to try it.

Sexual Dysfunction Across Female Life Stages

Sexual dysfunction is not a single experience, and the right treatment depends heavily on where you are in your reproductive life.

Reproductive Years and Hormonal Contraception

Women of reproductive age on hormonal contraception sometimes notice reduced libido. Combined oral contraceptives can suppress free testosterone levels by increasing sex hormone-binding globulin (SHBG), which may blunt desire. A 2019 review in the European Journal of Contraception found that approximately 15-22% of women on combined oral contraceptives report sexual side effects.

If this describes you, flibanserin is FDA-approved for premenopausal women and may be an appropriate conversation to have with your provider. Sildenafil is not the right tool here because the mechanism does not address the androgen pathway.

PCOS and Sexual Dysfunction

Women with polycystic ovary syndrome (PCOS) have a complex hormonal environment: often elevated androgens alongside insulin resistance and, in many cases, elevated SHBG despite the androgen excess. Research published in the Journal of Sexual Medicine found that women with PCOS report higher rates of sexual dysfunction compared with controls, driven in part by body image concerns, depression, and menstrual irregularity. Treating the underlying PCOS with lifestyle intervention, metformin, or inositol may improve sexual function more effectively than addressing the symptom directly.

Perimenopause

Perimenopause, the transition typically beginning in the mid-40s, brings fluctuating estrogen and progesterone. Vasomotor symptoms, sleep disruption, mood changes, and declining genital tissue responsiveness all affect sexual experience. This is the life stage where genitourinary syndrome of menopause (GSM) begins to develop, causing vaginal dryness, tissue thinning, and reduced engorgement capacity.

For perimenopausal women, the evidence base most strongly supports low-dose vaginal estrogen for GSM symptoms. The Menopause Society's 2023 position statement recommends vaginal estrogen as first-line treatment for GSM, and BCBS NC plans typically cover vaginal estrogen with a prescription.

Flibanserin's FDA approval does not extend to menopausal women, though some providers prescribe it off-label in the perimenopausal period.

Post-Menopause

After menopause, estrogen deficiency accelerates GSM changes. Libido changes are also common, with declining testosterone production from both the ovaries and adrenal glands playing a role. Ospemifene (Osphena), a selective estrogen receptor modulator taken orally, is FDA-approved for moderate to severe dyspareunia due to menopause and is a covered benefit on many BCBS NC plans.

Testosterone therapy for female sexual dysfunction, including post-menopausal HSDD, remains off-label in the United States because no testosterone formulation is FDA-approved for women. The data from the APHRODITE trial and others support its efficacy, but the insurance coverage picture mirrors that of sildenafil for women: generally not covered for sexual dysfunction.

Pregnancy and Lactation: What Every Woman Must Know

Sildenafil in Pregnancy

Sildenafil is not approved for use in pregnancy. The experimental STRIDER trials (Sildenafil TheRapy In Dismal prognosis Early-onset fetal growth Restriction) examined whether sildenafil could improve uteroplacental blood flow in pregnancies complicated by severe early-onset fetal growth restriction. The Dutch arm of the trial was halted early in 2018 after an excess of neonatal deaths due to pulmonary hypertension was observed in the sildenafil group compared with placebo.

This finding is significant. Sildenafil should not be used in pregnancy. If you are pregnant and were previously using sildenafil for any indication, stop and contact your obstetric provider immediately.

The FDA classifies sildenafil as Pregnancy Category B based on animal data showing no fetal harm, but the STRIDER findings represent concerning human evidence that overrides reassuring animal data. Do not rely on the animal-data category alone.

Lactation

Data on sildenafil transfer into breast milk are limited. A small pharmacokinetic study found that sildenafil and its active metabolite are present in breast milk at low levels, with a calculated relative infant dose of approximately 0.9%, which is generally below the 10% threshold considered safe. The Drugs and Lactation Database (LactMed) suggests that sildenafil is unlikely to cause adverse effects in a breastfed infant, but the data set is small and the evidence is not definitive.

If you are breastfeeding and considering sildenafil for PAH (the one FDA-approved indication in women), discuss timing of doses relative to feeding with your provider to minimize infant exposure.

Flibanserin in Pregnancy and Lactation

Flibanserin is not recommended in pregnancy. Animal reproduction studies showed no major teratogenicity at low doses, but human data are essentially absent. The FDA label advises women to use effective contraception while taking flibanserin and to discontinue it if pregnancy is confirmed.

No adequate data exist on flibanserin transfer into breast milk. Until data are available, flibanserin should be avoided during breastfeeding.

Bremelanotide in Pregnancy and Lactation

Bremelanotide is contraindicated in pregnancy. Animal studies showed embryotoxicity at doses relevant to human exposure. The FDA label states clearly that bremelanotide should be discontinued if pregnancy occurs. Women of reproductive potential should use effective contraception during treatment.

Lactation data for bremelanotide are absent. Its use during breastfeeding is not recommended.

Who This Is Right For (and Who Should Look Elsewhere)

Women Most Likely to Benefit from Pursuing Flibanserin or Bremelanotide Coverage

• Premenopausal women with documented HSDD causing personal distress (the DSM-5 criterion for FSIAD)
• Women whose sexual dysfunction is not explained by a relationship factor, another medical condition, or medication side effect
• Women who have already tried psychosexual therapy or counseling and still experience symptoms
• Women whose providers can document the diagnosis formally and support a prior authorization request

Women for Whom the Insurance Conversation May Look Different

• Postmenopausal women with GSM: prioritize vaginal estrogen or ospemifene, both of which have clearer BCBS NC coverage pathways
• Women with SSRI-induced sexual dysfunction: talk to your prescribing provider first about switching to an SSRI or SNRI with a less pronounced sexual side-effect profile (bupropion, for example, has data supporting improved sexual function)
• Women with PCOS: treating insulin resistance and hormonal imbalance often improves sexual function without a specific sexual dysfunction drug
• Women trying to conceive: none of the sexual dysfunction drugs discussed here are safe to use while trying to conceive or during pregnancy

When to Appeal a BCBS NC Denial

If BCBS NC denies coverage for flibanserin or bremelanotide, you have the right to appeal. The appeal process involves:

1. An internal appeal submitted to BCBS NC with supporting clinical documentation.
2. If denied again, an independent external review by a third-party organization.
3. In North Carolina, the North Carolina Department of Insurance oversees external review and consumer complaints.

Your provider's letter of medical necessity is the single most important document in any appeal. It should cite the DSM-5 diagnosis, the duration of symptoms, the degree of personal distress, and any prior treatments attempted.

The Cost Reality Without Coverage

If coverage is not available, out-of-pocket costs vary considerably by drug:

• Generic sildenafil 50 mg (30 tablets): approximately $30 to $80 with GoodRx coupons at major North Carolina pharmacies
• Flibanserin (Addyi) 100 mg (30 tablets): list price over $800 per month, though the manufacturer Sprout Pharmaceuticals offers patient assistance programs that can reduce this significantly for eligible women
• Bremelanotide (Vyleesi) 1.75 mg autoinjectors: list price over $1,000 per month; the manufacturer AMAG Pharmaceuticals has offered savings programs for commercially insured patients

The cost gap between off-label generic sildenafil and the FDA-approved female sexual dysfunction drugs is substantial. This is a real-world factor that shapes many women's choices, even when the approved drugs may be more appropriate.

Telehealth and BCBS NC Coverage

BCBS NC covers telehealth visits for many services, including gynecology and women's health consultations. A telehealth visit with a licensed women's health NP or OB-GYN can initiate the prescribing and prior authorization process for flibanserin or bremelanotide without requiring an in-person appointment.

Under North Carolina telehealth parity laws and the extensions of pandemic-era federal telehealth policies, many BCBS NC plans cover telehealth visits at the same cost-sharing rate as in-person visits. Confirm your specific plan's telehealth benefits before your appointment.

Pulmonary Arterial Hypertension: The One Case Where BCBS NC Does Cover Sildenafil for Women

Women make up approximately 70-80% of PAH diagnoses, making this a genuinely women-centered condition. Sildenafil (Revatio 20 mg three times daily) is FDA-approved for PAH and is covered by most BCBS NC plans with prior authorization.

If you have been diagnosed with PAH and your cardiologist or pulmonologist has recommended Revatio, the coverage pathway is entirely different from the sexual dysfunction context. Work with your specialist's office to complete the prior authorization process, which will typically require documentation of your PAH diagnosis, functional class, and any prior PAH treatments.

The 20 mg Revatio dose for PAH and the 25 to 100 mg Viagra dose for erectile dysfunction (or off-label female sexual dysfunction) are not equivalent or interchangeable from an insurance perspective, even though the active molecule is the same.